Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers

Study Identifier
GLYX13-C-101
CT.gov Identifier
NCT01014650
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Healthy Volunteer
    • Study Drug
  • GLYX-13
  • IV normal saline
    • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18 - 55 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * clinical laboratory values \< 2x the upper limit of normal * ability to understand the requirements of the study and provide informed consent
    Exclusion Criteria:
    * alcohol abuse * abuse of illicit substances * current smoker * currently taking prescription medications (other than for birth control) * history of allergy to NMDA receptor ligands * received another investigational drug within 30 days * psychiatric disease

    Protocol Summary

    The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of a single IV dose of GLYX-13, an N-Methyl-D-aspartate (NMDA) receptor glycine site functional partial agonist, in normal, healthy human volunteers.

    Study Locations

    Location
    Status
    Location
    Lotus Clinical Research
    Pasadena, California, United States, 91105
    Status
    Not applicable